Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.70 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nyx-2925 SCHEMBL18119906 | 1.00 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL18119905 | 1.00 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL17712358 | 1.00 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Risevistinel SCHEMBL18121976 | 1.00 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL19614471 | 1.00 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL23327990 | 0.99 | GRIN2B (0.69) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL27242082 | 0.99 | GRIN2B (0.69) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL27242059 | 0.99 | GRIN2B (0.69) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL27242083 | 0.99 | GRIN2B (0.69) | GRIN2BGRIN2CJAK3 | |
| SCHEMBL17716631 | 0.91 | GRIN2B (0.59) | GRIN2BGRIN2CJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352024-A1 | METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2024-10-24 | — | — | US | disclosed |
| US-12012413-B2 | Methods of treating painful diabetic peripheral neuropathy | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2024-06-18 | — | — | US | disclosed |
| US-20210139489-A1 | METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-05-13 | — | — | US | disclosed |
| EP-3458458-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10196401-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-04-05 | — | — | US | disclosed |
| US-9932347-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9925169-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170333395-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885JAK3 4530/4885 |
| US-10196401-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885JAK3 4530/4885 |
| US-20170333395-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885JAK3 4606/4885 |
| US-20210139489-A1 | METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY | LPXN, PMP22, DPP4 | GRIN2B 689/4885GRIN2C 721/4885JAK3 3561/4885 |
| US-12012413-B2 | Methods of treating painful diabetic peripheral neuropathy | LPXN, PMP22, DPP4 | GRIN2B 689/4885GRIN2C 721/4885JAK3 3561/4885 |
| US-20240352024-A1 | METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY | LPXN, PMP22, DPP4 | GRIN2B 689/4885GRIN2C 721/4885JAK3 3561/4885 |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885JAK3 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.